$VNRX
VOLITIONRX LTD Stock $vnrx

$vnrx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000147793223006106 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$165.2K	$216.3K
YoY Change	405.02%	444.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.168M	$4.314M
YoY Change	-2.81%	-11.23%
% of Gross Profit
Research & Development	$4.651M	$5.451M
YoY Change	24.43%	66.23%
% of Gross Profit
Depreciation & Amortization	$300.0K	$288.3K
YoY Change	0.8%	27.91%
% of Gross Profit
Operating Expenses	$8.818M	$9.765M
YoY Change	9.88%	19.98%
Operating Profit	-$8.653M	-$9.549M
YoY Change	8.26%	17.9%
Interest Expense	-$50.00K	-$31.21K
YoY Change	-640.54%	20.18%
% of Operating Profit
Other Income/Expense, Net	$199.9K	-$2.241K
YoY Change	16.58%	-100.57%
Pretax Income	-$8.450M	-$9.551M
YoY Change	8.16%	23.53%
Income Tax
% Of Pretax Income
Net Earnings	-$8.453M	-$9.551M
YoY Change	8.2%	23.53%
Net Earnings / Revenue	-5116.6%	-4415.55%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.11	-$0.14
COMMON SHARES
Basic Shares Outstanding	78.14M shares	63.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.81M	$19.74M
YoY Change	-34.15%	18.01%
Cash & Equivalents	$10.81M	$19.74M
Short-Term Investments
Other Short-Term Assets	$493.4K	$542.6K
YoY Change	15.75%	-44.29%
Inventory
Prepaid Expenses	$860.8K	$1.025M
Receivables	$34.44K	$196.5K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$12.20M	$21.51M
YoY Change	-30.99%	15.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.305M	$5.455M
YoY Change	8.69%	13.47%
Goodwill
YoY Change
Intangibles	$48.28K	$67.72K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.844M	$6.054M
YoY Change	3.1%	6.24%
TOTAL ASSETS
Total Short-Term Assets	$12.20M	$21.51M
Total Long-Term Assets	$5.844M	$6.054M
Total Assets	$18.04M	$27.56M
YoY Change	-22.71%	13.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.060M	$3.493M
YoY Change	24.0%	34.22%
Accrued Expenses	$2.868M	$3.391M
YoY Change	-6.57%	4.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.258M	$1.199M
YoY Change	18.17%	10.53%
Total Short-Term Liabilities	$17.65M	$18.80M
YoY Change	3.98%	8.37%
LONG-TERM LIABILITIES
Long-Term Debt	$2.086M	$2.452M
YoY Change	-8.3%	40.68%
Other Long-Term Liabilities	$320.0K	$340.3K
YoY Change	-28.78%	-34.49%
Total Long-Term Liabilities	$3.238M	$2.452M
YoY Change	42.33%	40.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.65M	$18.80M
Total Long-Term Liabilities	$3.238M	$2.452M
Total Liabilities	$20.89M	$22.44M
YoY Change	1.91%	10.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$193.9M	-$185.5M
YoY Change	21.16%	21.83%
Common Stock	$78.34K	$78.14K
YoY Change	36.26%	45.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.043M	$5.844M
YoY Change
Total Liabilities & Shareholders Equity	$18.04M	$27.56M
YoY Change	-22.71%	13.2%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$8.453M	-$9.551M
YoY Change	8.2%	23.53%
Depreciation, Depletion And Amortization	$300.0K	$288.3K
YoY Change	0.8%	27.91%
Cash From Operating Activities	-$8.420M	-$7.348M
YoY Change	23.48%	17.27%
INVESTING ACTIVITIES
Capital Expenditures	$280.0K	$301.4K
YoY Change	-186.02%	-155.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$280.0K	-$301.4K
YoY Change	-13.98%	-44.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-280.0K	17.34M
YoY Change	-104.16%	-3867.97%
NET CHANGE
Cash From Operating Activities	-8.420M	-7.348M
Cash From Investing Activities	-280.0K	-301.4K
Cash From Financing Activities	-280.0K	17.34M
Net Change In Cash	-8.980M	9.691M
YoY Change	2048.63%	-233.36%
FREE CASH FLOW
Cash From Operating Activities	-$8.420M	-$7.348M
Capital Expenditures	$280.0K	$301.4K
Free Cash Flow	-$8.700M	-$7.649M
YoY Change	33.98%	33.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. In addition, the Company has considered the potential impact of certain economic factors, including inflation, rising interest rates, and recessionary pressures, on its business and operations. Although the full impact of these factors is unknown and cannot be reasonably estimated, the Company believes it has made appropriate accounting estimates and assumptions based on the facts and circumstances available as of the reporting date. However, the Company’s actual results may differ materially and adversely from these estimates and assumptions, which may result in material effects on the Company’s financial condition, results of operations, and liquidity. To the extent there are material differences between the estimates and the actual results, the Company’s condensed consolidated financial statements could be materially affected.</p>
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	196487	usd
	vnrx	Terms Of License Agreement TermsOfLicenseAgreement	Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	10000000.0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5455395	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8705875	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3312863	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5393012	usd
	us-gaap	Depreciation Depreciation	517921	usd
	us-gaap	Depreciation Depreciation	407059	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42392	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42647	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	43050	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	24672	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	67722	usd
	vnrx	Stockoptions Cancelled StockoptionsCancelled	273067	shares
	vnrx	Equity Incentive Rsu EquityIncentiveRsu	146500	shares
	vnrx	Incentive Rsu Issued IncentiveRsuIssued	101576	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0000093314
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218142	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245163	usd
CY2023Q2	vnrx	Current Portion Of Grant Repayable CurrentPortionOfGrantRepayable	42558	usd
	dei	Entity File Number EntityFileNumber	001-36833
	dei	Entity Registrant Name EntityRegistrantName	VOLITIONRX LIMITED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1949078
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1489 West Warm Springs Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89014
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	650–1351
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	VNRX
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	78136364	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19743274	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10867050	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	196487	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72609	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1024728	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	784920	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	542639	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447566	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	21507128	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12172145	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5455395	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5393012	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	530669	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	619392	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	67722	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	110505	usd
CY2023Q2	us-gaap	Assets Assets	27560914	usd
CY2022Q4	us-gaap	Assets Assets	18295054	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3492746	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3043008	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3391347	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2872247	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10000000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10000000	usd
CY2023Q2	us-gaap	Management Fee Payable ManagementFeePayable	72997	usd
CY2022Q4	us-gaap	Management Fee Payable ManagementFeePayable	71119	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1199386	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1066700	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	47419	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46014	usd
CY2022Q4	vnrx	Current Portion Of Grant Repayable CurrentPortionOfGrantRepayable	41836	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	337989	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18802584	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17386087	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2452305	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2779240	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	419804	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	436132	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	340314	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	400091	usd
CY2023Q2	vnrx	Grant Repayable Net Of Current Portion GrantRepayableNetOfCurrentPortion	427732	usd
CY2022Q4	vnrx	Grant Repayable Net Of Current Portion GrantRepayableNetOfCurrentPortion	420466	usd
CY2023Q2	vnrx	Long Term Liabilities Total LongTermLiabilitiesTotal	3640155	usd
CY2022Q4	vnrx	Long Term Liabilities Total LongTermLiabilitiesTotal	4035929	usd
CY2023Q2	us-gaap	Liabilities Liabilities	22442739	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21422016	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	78136364	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57873379	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	78137	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	57873	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	191065293	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164397468	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	208331	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	227097	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185507956	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167257429	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	5843805	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2574991	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-725630	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-551971	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118175	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3126962	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27560914	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18295054	usd
CY2023Q2	vnrx	Service Revenue ServiceRevenue	50163	usd
CY2022Q2	vnrx	Service Revenue ServiceRevenue	10046	usd
	vnrx	Service Revenue ServiceRevenue	55519	usd
	vnrx	Service Revenue ServiceRevenue	70300	usd
CY2023Q2	vnrx	Product Revenue ProductRevenue	166147	usd
CY2022Q2	vnrx	Product Revenue ProductRevenue	29706	usd
	vnrx	Product Revenue ProductRevenue	310599	usd
	vnrx	Product Revenue ProductRevenue	83663	usd
CY2023Q2	us-gaap	Revenues Revenues	216310	usd
CY2022Q2	us-gaap	Revenues Revenues	39752	usd
	us-gaap	Revenues Revenues	366118	usd
	us-gaap	Revenues Revenues	153963	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5451287	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3279323	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10356965	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6869376	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2644957	usd
CY2023Q2	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.14
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3085840	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5226660	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5687992	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1669102	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1774064	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3376559	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3373047	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	9765346	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8139227	usd
	us-gaap	Operating Expenses OperatingExpenses	18960184	usd
	us-gaap	Operating Expenses OperatingExpenses	15930415	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9549036	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8099475	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18594066	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15776452	usd
CY2023Q2	vnrx	Income From Grants IncomeFromGrants	0	usd
CY2022Q2	vnrx	Income From Grants IncomeFromGrants	393440	usd
	vnrx	Income From Grants IncomeFromGrants	165795	usd
	vnrx	Income From Grants IncomeFromGrants	393440	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	27109	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	11161	usd
	us-gaap	Interest Income Other InterestIncomeOther	84757	usd
	us-gaap	Interest Income Other InterestIncomeOther	11163	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	58321	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	37129	usd
	us-gaap	Interest Expense Other InterestExpenseOther	109643	usd
	us-gaap	Interest Expense Other InterestExpenseOther	78161	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	28971	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	28971	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2241	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	367472	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	169880	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	326442	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-9551277	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-7732003	usd
	us-gaap	Profit Loss ProfitLoss	-18424186	usd
	us-gaap	Profit Loss ProfitLoss	-15450010	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	80298	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	82302	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	173659	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	166279	usd
CY2023Q2	vnrx	Net Income Loss Attributable To Volition Rx Limited Stockholders NetIncomeLossAttributableToVolitionRxLimitedStockholders	-9470979	usd
CY2022Q2	vnrx	Net Income Loss Attributable To Volition Rx Limited Stockholders NetIncomeLossAttributableToVolitionRxLimitedStockholders	-7649701	usd
	vnrx	Net Income Loss Attributable To Volition Rx Limited Stockholders NetIncomeLossAttributableToVolitionRxLimitedStockholders	-18250527	usd
	vnrx	Net Income Loss Attributable To Volition Rx Limited Stockholders NetIncomeLossAttributableToVolitionRxLimitedStockholders	-15283731	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	37712	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	214097	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-18766	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	96193	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9513565	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7517906	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18442952	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15353817	usd
CY2022Q2	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.14
	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.29
	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.28
CY2023Q2	vnrx	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	66884368	shares
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-115548	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16092324	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2654950	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	501986	usd
CY2022Q2	vnrx	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	53810500	shares
	vnrx	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	63613224	shares
	vnrx	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	53803076	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3126962	usd
CY2023Q1	vnrx	Common Stock Issued For Cash Net Of Issuance Costs Amount CommonStockIssuedForCashNetOfIssuanceCostsAmount	8427655	usd
CY2023Q1	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2023Q1	vnrx	Common Stock Repurchased Amount CommonStockRepurchasedAmount	-31772	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	693657	usd
CY2023Q1	vnrx	Tax Withholdings Paid Related To Stock Based Compensation TaxWithholdingsPaidRelatedToStockBasedCompensation	-14336	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-56478	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-8872909	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2981145	usd
CY2023Q2	vnrx	Common Stock Issued For Cash Net Of Issuance Costs And Allocation To Warrant Liability Amount CommonStockIssuedForCashNetOfIssuanceCostsAndAllocationToWarrantLiabilityAmount	17086606	usd
CY2023Q2	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	592174	usd
CY2023Q2	vnrx	Tax Withholdings Paid Related To Stock Based Compensation TaxWithholdingsPaidRelatedToStockBasedCompensation	-65895	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	37712	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-9551277	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118175	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17722105	usd
CY2022Q1	vnrx	Common Stock Issued For Cash Net Of Issuance Costs Amount CommonStockIssuedForCashNetOfIssuanceCostsAmount	9467	usd
CY2022Q1	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	915031	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-117904	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7718007	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10810692	usd
CY2022Q2	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	854304	usd
CY2022Q2	vnrx	Tax Withholdings Paid Related To Stock Based Compensation TaxWithholdingsPaidRelatedToStockBasedCompensation	-67988	usd
CY2022Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	214097	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-7732003	usd
	us-gaap	Net Income Loss NetIncomeLoss	18424186	usd
	us-gaap	Net Income Loss NetIncomeLoss	15450010	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	560313	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	449706	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	127210	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	133260	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1285831	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1769335	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	28971	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	166351	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	337701	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	196487	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3963	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	95073	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	187337	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9987488	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	961764	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1088936	usd
	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	9019	usd
	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	2958	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-125393	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	665942	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-501986	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-665942	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25881221	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9464	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	80231	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	67988	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	31772	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	vnrx	Proceeds From Long Term Debt ProceedsFromLongTermDebt	216908	usd
	vnrx	Proceeds From Long Term Debt ProceedsFromLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	475965	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	631667	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	23188	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	24384	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25486973	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-714575	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16439	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184595	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8876224	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3850872	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10867050	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20581313	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19743274	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16730441	usd
	us-gaap	Interest Paid Net InterestPaidNet	109643	usd
	us-gaap	Interest Paid Net InterestPaidNet	78161	usd
	vnrx	Common Stock Issued On Cashless Exercises Of Stock Options And Warrants CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrants	102	usd
	vnrx	Common Stock Issued On Cashless Exercises Of Stock Options And Warrants CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrants	72	usd
	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	239772	usd
	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	366960	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	vnrx	Non Cash Note Payable NonCashNotePayable	356258	usd
	vnrx	Non Cash Note Payable NonCashNotePayable	620549	usd
CY2023Q2	vnrx	Warrant Liability WarrantLiability	337989	usd
CY2022Q4	vnrx	Warrant Liability WarrantLiability	0	usd
	vnrx	Fair Value Of Warrant Liability Issuance FairValueOfWarrantLiabilityIssuance	366960	usd
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	-28971	usd
CY2023Q2	vnrx	Warrant Liability WarrantLiability	337989	usd
	vnrx	Net Income Loss Since Inception NetIncomeLossSinceInception	185500000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1228413	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9077212	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3621817	usd
CY2023Q2	vnrx	Common Stock Share Authorized CommonStockShareAuthorized	100000000	shares
CY2023Q2	vnrx	Common Stock Price Per Sahres CommonStockPricePerSahres	0.001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	78136364	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57873379	shares
	vnrx	Stock Options Granted Shares StockOptionsGrantedShares	273067	shares
	vnrx	Rsus Held For Taxes RsusHeldForTaxes	44924	usd
CY2023Q1	vnrx	Common Stock Shares Expired CommonStockSharesExpired	125000	shares
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.037	pure
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.037	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.7196	pure
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.7156	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y10D
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y10D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0	pure
	vnrx	Total Fair Value Of Warrants TotalFairValueOfWarrants	337989	usd
CY2023Q2	vnrx	Total Fair Value Of Warrants TotalFairValueOfWarrants	366960	usd
	vnrx	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P4Y3M29D
	vnrx	Compensation Expense Rsus CompensationExpenseRsus	167717	shares
	vnrx	Rsu Expense RsuExpense	280719	usd
	vnrx	Equity Incentive Rsu EquityIncentiveRsu	146500	shares
	vnrx	Incentive Rsu Issued IncentiveRsuIssued	101576	shares
	vnrx	Rsus Held For Taxes RsusHeldForTaxes	44924	usd
	vnrx	Equity Incentive Rsu During Period For Cancelled Stock EquityIncentiveRsuDuringPeriodForCancelledStock	63343	shares
	vnrx	Incentive Rsus Cancelled IncentiveRsusCancelled	63343	shares
CY2023Q2	vnrx	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	41416	usd
CY2023Q2	vnrx	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	32656	usd
CY2023Q2	vnrx	Operating Leases Future Minimum Lease Payment Due OperatingLeasesFutureMinimumLeasePaymentDue	74072	usd
CY2023Q2	vnrx	Grant Repyable GrantRepyable	470290	usd
CY2023Q2	vnrx	Long Term Debt Payable LongTermDebtPayable	3651691	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	711033	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	787000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	559176	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	304115	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	454520	usd
CY2023Q2	vnrx	Long Term Debt Due LongTermDebtDue	4044257	usd
CY2023Q2	vnrx	Long Term Debt Less Amount Representing Interest LongTermDebtLessAmountRepresentingInterest	-392566	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	3651691	usd
CY2023Q2	vnrx	Payments For Future Research And Collobration PaymentsForFutureResearchAndCollobration	959406	usd
CY2023Q2	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Year FutureMinimumCollaborativeAgreementObligationsOfFiscalYear	877633	usd
CY2023Q2	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Year One To Five FutureMinimumCollaborativeAgreementObligationsOfFiscalYearOneToFive	81773	usd
CY2023Q2	vnrx	Collaborative Agreement Obligations CollaborativeAgreementObligations	959406	usd
CY2020Q4	vnrx	Aggerate Amount Payable Description AggerateAmountPayableDescription	under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million
CY2023Q2	vnrx	Amount Repayable AmountRepayable	428669	usd
CY2023Q2	vnrx	Payable By Company For Services Rendered PayableByCompanyForServicesRendered	1316023	usd
CY2023Q1	vnrx	First Insurance Funding Amount FirstInsuranceFundingAmount	356258	usd
CY2023Q1	vnrx	Fixed Interest Rate FixedInterestRate	0.0742	pure
CY2023Q1	vnrx	Line Of Credit Facility Expiration Dates One LineOfCreditFacilityExpirationDatesOne	November 2023
CY2023Q2	vnrx	Insurance Principal Balance Payable InsurancePrincipalBalancePayable	197921	usd
CY2023Q2	vnrx	Accrued Compensation Expense AccruedCompensationExpense	1069523	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	724339	usd
	vnrx	Amortised Of Outstanding Award Amount One AmortisedOfOutstandingAwardAmountOne	478479	usd
	vnrx	Amortised Of Outstanding Award Amount AmortisedOfOutstandingAwardAmount	245861	usd
	vnrx	Un Amortised Of Outstanding Award UnAmortisedOfOutstandingAward	873837	usd

Files In Submission

Name	View Source	Status
vnrx-20230630_cal.xml	Edgar Link	unprocessable
0001477932-23-006106-index-headers.html	Edgar Link	pending
0001477932-23-006106-index.html	Edgar Link	pending
0001477932-23-006106.txt	Edgar Link	pending
0001477932-23-006106-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vnrx-20230630.xsd	Edgar Link	pending
vnrx_10q.htm	Edgar Link	pending
vnrx_ex311.htm	Edgar Link	pending
vnrx_ex312.htm	Edgar Link	pending
vnrx-20230630_lab.xml	Edgar Link	unprocessable
vnrx-20230630_def.xml	Edgar Link	unprocessable
vnrx-20230630_pre.xml	Edgar Link	unprocessable
vnrx_10q_htm.xml	Edgar Link	completed
vnrx_ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VNRX
VOLITIONRX LTD Stock $vnrx

2023 Q3 Form 10-Q Financial Statement

#000147793223006106 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX VOLITIONRX LTD Stock $vnrx

2023 Q3 Form 10-Q Financial Statement

#000147793223006106 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX
VOLITIONRX LTD Stock $vnrx